Latest: High-throughput cryo-EM epitope mapping of SARS-CoV-2 spike protein antibodies with...

Latest: The 2022 AACC Annual Scientific Meeting and Clinical Lab Expo: Clinical laboratory news...

Latest: How biopharmaceutical manufacturing has changed in the post-pandemic era: Re-analyzing...

Latest: THCVA single now available for your potency analysis: Upgrade to superior stability

Latest: Sustainable lab equipment: 6 reviews on products that can help your lab become more...

Latest: Food safety testing webinars on demand: Mycotoxins, pesticides and food contact materials

Latest: 5 upcoming webinars to broaden your research horizons

High-throughput cryo-EM epitope mapping of SARS-CoV-2 spike protein antibodies with Utrecht...

Alternatives to ELISA: Ultrasensitive immunoassays that use less sample volume and offer higher...

FDA authorizes Quest Diagnostics' proprietary monkeypox test for emergency use

Parkinson’s breakthrough can diagnose disease from skin swabs in 3 minutes

Upcoming webinar: Discover a platform designed to make the perfect lipid nanoparticle

Find sustainable lab equipment that doesn’t compromise efficiency

Managing the risk of nitrosamines in medicinal drugs

Your essential guide to preparative LC

Choosing the best components for your diagnostic kit

RNA isolation and integrity from primary tumor PDECs cultured in GrowDex compared with Cultrex

Amersham HCP CHO solution: An ELISA with broad sample compatibility and high sensitivity

DNA/RNA Purification and Analysis

Virtual Cancer and Immunology Summit

Although traditional colorimetric enzyme-linked immunosorbent assays (ELISA) are the gold standard for protein detection in biomarker research, there are now more sensitive options available for detecting and quantifying physiological proteins, specifically those present in low abundance.

These ultrasensitive immunoassays include Immuno-Quantitative ELISA (IQELISA™), a real-time PCR-based assay, and digital single molecule array (SIMOA™), a bead-based ELISA assay. In this SelectScience® article, we dig deeper into these next-generation immunoassays, speaking with scientist-turned-industry professional, Dr. Valerie Jones, Sales, Marketing, and Technical Support Director at RayBiotech, a leading manufacturer of multiplex immunoassay technologies.

Below, we highlight how these ultrasensitive immunoassays work, when they are most applicable, and why labs may benefit from choosing these assays over standard ELISAs.

VJ: Traditional colorimetric ELISA is definitely considered the gold standard. But one of the drawbacks of this technique is the quantity of sample consumed. Often, a sample volume of 50–100 µL is required for every analyte measured. That may not sound like a lot in in vitro cell culture applications, but in the case of rare or clinical samples, such as biopsy tissue, this can limit the number of analytes that can be measured, thereby limiting research potential.

Another drawback of the colorimetric sandwich ELISA is its sensitivity – the lowest possible detection limit is around the lower picograms/mL range. As a result, several bioactive proteins, particularly cytokines, that exist in biological fluids in much lower concentrations may go undetected.

Ultrasensitive immunoassays, on the other hand, require smaller sample volumes and can be multiplexed, helping researchers make the most of limited samples and quantify previously under-studied low-abundance biomarkers. 

A comparison of standard ELISA, IQELISA™, SIMOA™. * = final volume per replicate after sample dilution.

VJ: IQELISA™ uses the principle of real-time immuno-PCR. This method is different from traditional sandwich ELISA in that the detection antibody is conjugated to a unique DNA barcode. Using PCR, this DNA barcode is amplified and stained in the presence of barcode-specific primers. A fluorescent dye binds to the DNA, and its signal, proportional to the amount of target protein, is measured using a real-time PCR instrument.

Using real-time PCR offers this technique a 23-fold increase in sensitivity when compared to sandwich ELISA. Because of this increased sensitivity, one can get away with using less sample volume, which is an obvious advantage.

SIMOA™, which stands for single molecule array, is a bead-based sandwich immunoassay. In this case, the antibody-coated beads, the sample, and the fluorescently conjugated detection antibody are mixed together to form immunocomplexes. This mixture is then applied to a cartridge with over 200,000 microwells, with each microwell only being able to hold one bead. This enables a precise fluorescent readout in the femtomolar range even when only a single molecule of the target analyte is bound to the bead. Compared to standard ELISA, the average sensitivity increase provided by SIMOA™ is 465-fold.     

VJ: If a researcher wants a quick-and-easy immunoassay with enhanced sensitivity that they can execute in one day – and they have access to real-time PCR instruments – then they can simply purchase an IQELISA™ kit.

SIMOA™, although more sensitive, requires a dedicated detector. If the researcher doesn't have the resources to procure that instrument, then we offer a service where samples can be shipped to our facility, and we’ll perform the assay and create a data report. While the turnaround here can take a week or two, taking advantage of this off-site service can be cost-effective in terms of saving on equipment purchases.

VJ: One of the primary areas where ultrasensitive immunoassays are being used is detecting cytokines and other secreted proteins that play a prominent role in cancer, neurodegenerative diseases, and infectious diseases. For example, in cancer, cytokines can promote tumorigenesis, angiogenesis, or metastasis. Additionally, they can mediate pathogenic inflammatory states seen in neurodegenerative and autoimmune diseases and can contribute to cytokine storms associated with acute infections. 

The challenge here is the dynamics of the cytokine secretion over time, where the local concentrations of these proteins can often fall to low picogram levels or lower. Using ultrasensitive immunoassays in these applications can give the researcher an edge as it can be used to reliably and reproducibly detect these biomarkers at lower concentrations. 

Some of the most popular targets from our portfolio include cytokines implicated in cancer, for example, interleukin-2 (IL-2), IL-1 alpha, IL-6, tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), as well as biomarkers in Alzheimer’s disease, such as neurofilament light chain (NFL) and tau protein, and a biomarker of heart disease, cardiac troponin.

VJ: We regularly work with scientists on their particular research needs. If the desired assay doesn't exist in our product line, we offer custom assay development tailored to the researcher’s goals. At times, these custom assays end up becoming a part of our growing portfolio so other labs can also use them in the future. In other cases, we enter into an exclusive agreement with the client. Either way, we do our best to help labs advance their research.

VJ: When implementing a new ultrasensitive immunoassay, it helps to shorten the learning curve by seeking support and training from technology providers. We assist all our customers on both the front-end and back-end of their research projects. Scientists consult with our in-house specialists on the experimental design and planning phases to make the most of their samples while staying within budget. We talk through all the different options available before they begin experiments.

On the other end, in the post-experiment phase, we offer assistance with data interpretation, data analysis, bioinformatics, biostatistics, and even protocol troubleshooting if optimal results aren’t being observed. Typically, we offer phone consultations, email, and live chat support, but on many occasions, we’ve also gone to research labs to provide in-person, hands-on support when necessary.

VJ: We are always on the hunt for superior, high-sensitivity platforms as well as better proteomic assays. Our focus is on precision sensitivity, ease of use, and high molecular content, and we’re continually trying to improve on all these aspects by adding more kits and services to our portfolio.